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Title: Impact of Hepatitis C treatment on behavioural change in relation to drug use in people 
who inject drugs: a systematic review 
Abstract 
Background: A systematic review was conducted to determine the impact of Hepatitis C (HCV) 
treatment on substance use behaviour in people who inject drugs (PWID).  
Methods: A search for peer reviewed journal articles from 1991 to present day was conducted 
using the following databases: PubMed, EMBASE, CINAHL and PsycINFO. Studies were 
appraised against the following inclusion criteria: recruitment of PWID for HCV treatment (either 
interferon alpha or direct acting antivirals based); measurement of behavioural change in 
relation to drug use; studies published in English.  
Results: Five studies investigating the impact of HCV treatment on behavioural change in 
relation to drug use amongst PWID were identified. Studies investigated the impact of HCV 
treatment on past month injecting drug use (four studies), injecting frequency (two studies), 
needle and syringe borrowing (two studies) and injecting equipment sharing (three studies). 
Three of the four studies assessing impact of treatment on past month injecting frequency found 
treatment significantly reduced the odds of participants reporting past month injecting at follow 
up. One study found that there was significant reduction in weekly injecting frequency between 
enrolment, treatment and follow up. No association was found between treatment engagement 
and needle and syringe borrowing. Two out of three studies reported a significant decrease in 
injecting equipment sharing between enrolment, treatment and follow up.  
Conclusions: Comparison and synthesis of results was challenging due to heterogeneity 
between studies. Moreover, four out of the five selected studies were conducted during the 
interferon era of treatment, possibly limiting the generalisability of the current review’s results to 
the new DAA treatment era. However, it is likely that engaging in treatment has a positive 
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impact upon patients’ injecting drug use and injection equipment sharing behaviour. This raises 
the possibility that this may be an opportune time for further harm reduction measures.  
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Hepatitis C; People who inject drugs; Injecting risk behaviours; Behaviour change; Systematic 
review  
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Introduction 
Hepatitis C (HCV) is a blood borne virus which affects around 71 million people globally (World 
Health Organisation, 2017; Blach et al., 2017). It is estimated that 39.2% of PWID are currently 
living with HCV infection worldwide (Grebely et al., 2019). HCV infection is a major contributor to 
morbidity and mortality among this population (Stanaway et al., 2016). Research has supported 
the treatment of active drug users for Hepatitis C, demonstrating successful adherence to 
treatment and favourable sustained viral response rates (Hajarizadeh et al., 2018). This 
highlights the feasibility and effectiveness of scaling up treatment services to reduce the 
prevalence of the disease, using “treatment as prevention” (TasP) models of elimination (E. J. 
Aspinall et al., 2013; Fraser et al., 2018). TasP models of elimination focus on treating PWID for 
HCV as they are the most at- risk population for acquiring the virus. Therefore, HCV elimination 
can be achieved by treating those at risk of continuous HCV transmission (Hellard, Doyle, 
Sacks- Davis, Thompson, & McBryde, 2014; Hellard et al., 2015; Hutchinson et al., 2015). 
However, testing, diagnosis and treatment rates of HCV infection among PWID have found to 
be inadequate in some settings, despite evidence that the incidence of HCV- related liver 
disease is on the rise (Socías et al., 2019; Thrift, El-Serag, & Kanwal, 2017; Wiessing et al., 
2014). Barriers to testing and treatment are complex, but include concerns among providers 
around ongoing risk behaviour, such as ongoing substance misuse, and the sharing of injecting 
paraphernalia; risk of reinfection; the worsening of psychiatric comorbidities; and poor treatment 
adherence (Grebely & Tyndall, 2011).  
In spite of these barriers to treatment, there is a suggestion that the benefits of engaging with 
HCV care stretch beyond liver morbidity outcomes. Studies report the positive impact of HCV 
status notification on reduction in drug use among PWID (E. Aspinall et al., 2014; Bruneau et 
al., 2013). PWID accessing HCV treatment have the opportunity to develop a therapeutic 
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relationship with healthcare professionals involved in their care, which may facilitate behavioural 
change (Spelman et al., 2015).  
Understanding the influence of treatment receipt on behaviour in relation to drug use in PWID 
may have an effect on treatment accessibility for this population, and may facilitate the 
development of supplementary support services to be offered with treatment. The objective of 
this review was to examine the literature investigating how, if at all, the behaviour of PWID 
changes in relation to drug use when undergoing HCV treatment and during follow up, including 
changes in injecting behaviour, injecting frequency, needle and/or syringe borrowing, and 
injecting equipment sharing.  
Methods 
This systematic review was conducted and reported in accordance with the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses (PRISMA) statement (Moher, Liberati, 
Tetzlaff, & Altman, 2009). The study was registered in PROSPERO (CRD42018116625). 
Search Strategy 
The International Prospective Register of Systematic Reviews (PROSPERO) was searched to 
confirm no similar review had already been conducted. A search for peer reviewed journal 
articles was conducted using PubMed, EMBASE, CINAHL and PsycINFO, on 9th November 
2018. A grey literature search of the International Network on Hepatitis in Substance Users 
(INHSU) conference abstracts was also conducted. This symposium was specifically targeted 
as it is dedicated to research focusing on Hepatitis C in the cohort of interest, namely PWID. A 
time parameter was implemented for studies conducted from 1991 to 2018, as 1991 was the 
year interferon became commercially available for treatment of Hepatitis C. An inclusive list of 
search terms in line with each search topic was generated to develop an effective search 
strategy. Both keywords and indexed subject headings (MeSH and EMTREE terms) were 
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included in the formulation of search strings for each database search. Search topics included 
“Hepatitis C treatment”, “behaviour change” and “drug use”. Table 1 includes a full list of search 
terms utilised in the search strategy, grouped by search topic. Manual searches of reference 
lists of selected studies were also conducted. Searches were limited to studies published in 
English.  
Study selection 
Fig. 1 shows a PRISMA flowchart of the selection process. Screening of the search strategy 
results was conducted by two reviewers. The first phase involved importing all citations into 
EndNote X8 and removing duplicate records. Titles were screened, and irrelevant records 
removed. Abstracts were then assessed using the inclusion and exclusion criteria (see Table 2). 
All remaining records were then subjected to a full text evaluation for eligibility.  
Data Extraction and Synthesis  
Data from selected studies was extracted using a piloted data extraction form by one reviewer 
(MC). The following variables were collected: first author, title, publication year, full paper or 
abstract, primary aim, study design, location, setting, total study duration, follow up period, 
sample characteristics, sample size, intervention, outcome/ measure of behaviour change, main 
results, conclusions. The authors of Malaguti et al. (2019) were contacted for clarification 
regarding follow up period in their study. The authors of Artenie et al. (2019) were contacted to 
obtain updated data, and they kindly provided an unpublished manuscript relating to their 
INHSU conference abstract. The data synthesis used a ESRC style quantitative narrative 
synthesis (Popay et al., 2006). This was used as there was too much heterogeneity between 
selected studies for meta- analysis.  
Quality Appraisal 
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Risk of bias in individual studies was assessed using the Quality Appraisal Checklist for 
quantitative intervention studies by NICE public health guidance (National Institute for Health 
and Care Excellence, 2012). The checklist enables both the evaluation of the study’s internal 
and external validity, addressing aspects of study design such as participant characteristics, 
definition of and allocation to intervention/control conditions, and methods of analyses. Each 
study was awarded separate overall quality ratings for internal and external validity, with ratings 
ranging from 1 to 3. Quality appraisal for four studies was independently conducted by two 
reviewers (MC and AM), with discrepancies in ratings resolved by discussion until consensus 
was met. A Cohen’s kappa coefficient (κ) was calculated to assess inter-rater agreement, κ = 
.61, p < .001. This kappa (κ) value represents a substantial agreement (Landis & Koch, 1977). A 
third reviewer (ER), along with the first reviewer (MC), conducted a quality appraisal for the fifth 
study. This was necessary to reduce bias as the second reviewer (AM) was an author of the 
study. A Cohen’s kappa coefficient (κ) was calculated to assess inter-rater agreement, κ = .68, p 
< .001, representing a substantial agreement (Landis & Koch, 1977).  
Results 
Search results 
The database search produced a total number of 863 records. After removing duplicates (n= 
141), a further 702 were removed after title and abstract screening. Twenty- one full text articles 
were assessed for eligibility, 16 were removed with reasons, leading to the final inclusion of 5 
studies (see Fig. 1). 
Characteristics of Selected Studies 
Characteristics and findings of selected studies are summarised in Table 3. Studies evaluated 
impact of treatment on drug use by recruiting participants from a number of settings including 
tertiary hospitals; GP and primary care clinics; community clinics; drug and alcohol treatment 
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clinics; private medical practices; and injecting equipment provision services. There were four 
prospective cohort studies and one retrospective cohort study. Two studies included 
comparison groups in their study design. Alavi et al. (2015) utilised PWID that did not receive 
treatment as their comparison group. Artenie et al. (2017) utilised three comparisons groups, 
namely PWID who did not engage in treatment post- diagnosis; PWID who did not engage in 
treatment due to spontaneous clearance of the virus; and HCV positive PWID who were not 
eligible for treatment due to contra-indications.  
Four studies investigated past month injecting drug use; two studies investigated injecting 
frequency; two studies investigated needle and syringe borrowing; and three studies 
investigated ancillary injecting equipment sharing. Of the five studies selected, four studies 
involved treatment with pegylated interferon alpha and/or ribavirin, with only one study involving 
treatment with direct acting antivirals (DAAs). Follow up periods ranged from 24 weeks to 2 
years. In the sampled studies, the majority of participants were Caucasian males, with a mean 
age ranging from 32- 47 years old, who had injected drugs in the last 6 months prior to study 
enrolment. Two of the five selected studies solely recruited participants with acute HCV infection 
(Alavi et al., 2015; Artenie et al., 2017). Recruiting patients for treatment with acute HCV 
infection is not reflective of standard clinical practice, as these patients have a 20-30% of 
spontaneous clearance during the acute phase of the infection, making treatment uneconomical 
at this stage (Aisyah, Shallcross, Hully, O’Brien & Hayward, 2018). However, effect on injecting 
behaviour may still be relevant.  
Risk of bias in individual studies 
Table 4 provides detailed quality appraisal scores for each included study. The results of the 
scoring process suggests that Artenie et al. (2017) was the methodologically most robust study. 
Overall, the selected studies scored very highly on external validity. However, several issues of 
internal validity can be discussed. For instance, the occurrence of losses to follow up may have 
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caused selection bias in several studies, with sizeable differences in socio-demographic 
characteristics between participants who remained, versus lost to follow up. For example, 
Midgard et al. (2017) found that participants who remained in 12 weeks follow up were more 
likely to be employed, have higher education levels, had less history of incarceration, and had 
injected more often in the last month, in comparison to those lost to follow up. Therefore, it is 
possible that those remaining in follow up were more likely, for instance, to have greater access 
to social support, impacting on their ability to engage in treatment and facilitate behavioural 
changes in relation to their drug use. Another issue of internal validity is the lack of comparison 
groups in some studies, e.g. Artenie et al. (2019) and Midgard et al. (2017), making it 
challenging to attribute behavioural changes to the intervention, i.e. HCV treatment. A final point 
to note is the quality assessment tool’s appraisal of the outcome variable’s reliability. According 
to the Quality Appraisal Checklist’s guidelines, outcome variables that are measured 
subjectively, e.g. self report, are to be scored poorly and could introduce information bias 
(National Institute for Health and Care Excellence, 2012). As all selected studies utilised a self-
reported measure of injecting risk behaviours, they were all poorly scored for this part of the 
appraisal process. However, research has demonstrated that self-reported drug use among 
PWID is reliable and valid (Darke, 1998). Therefore, it is the opinion of the authors that the 
selected studies rate more highly for study design appraisal.
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Results of individual studies 
Impact of treatment on past month injecting drug use 
Four studies investigated the impact of treatment on past month injecting drug use at various 
time points during treatment and follow up, assessed dichotomously (Alavi et al., 2015; Artenie 
et al., 2017; Artenie et al., 2019; Midgard et al., 2017). Alavi et al. (2015) reported no 
association between HCV treatment and past month drug use during 24 weeks follow up, when 
comparing PWID who did and did not receive treatment (aOR 1.06, 95% CI 0.93- 1.21, n= 124). 
However, this study did not differentiate between participants based on their reasons for not 
engaging in treatment after study enrolment, possibly explaining the non-significant results of 
the study as untreated participants are arguably a more heterogeneous cohort. A second study 
by Artenie et al. (2017) did make this distinction, evaluating the impact of treatment on injecting 
drug use at one year follow up when comparing people who received treatment, and three 
comparison groups: people who spontaneously cleared the virus and did not require treatment; 
people who were not eligible for treatment due to contra-indications to therapy; and people who 
voluntarily chose not to engage in HCV care. Results showed that the received treatment group 
were less likely to report drug use at follow up in comparison to the voluntary non- engagement 
group (aOR 0.18, 95% CI 0.04- 0.76, n=87). The odds of reporting drug use at follow up 
amongst the spontaneous clearance (aOR 0.34, 95% CI 0.08–1.40, n=87) and contra- 
indications to therapy groups (aOR 0.24, 95% CI 0.05– 1.22, n= 87), were not significantly lower 
in comparison to the voluntary non- engagement group. This finding is supported by Midgard et 
al. (2017) who found that there was a significant reduction in any past month injecting drug use 
during treatment and 12 week follow up (OR 0.89, 95% CI 0.83– 0.95, n= 93), with the likelihood 
of injecting halved at treatment completion compared to study enrolment. A fourth study 
evaluated the impact of DAA based treatment on past month injecting drug use and found that 
there was an overall significant reduction in opioid injecting (OR: 0.95, 95% CI 0.92- 0.99, n= 
10
190) between treatment initiation and 2 year follow up (Artenie et al., 2019). However, no 
reduction in stimulant (cocaine and amphetamine) injecting was reported (OR 0.98, 95% CI 
0.94-1.02, n=190). 
Impact of treatment on injecting frequency 
Two studies investigated the impact of treatment on injecting frequency. Midgard et al. (2017) 
measured ≥ daily injecting as a proxy for past month injecting frequency, and found that the 
proportion of participants who reported ≥ daily injecting did not significantly change during 
treatment and follow up (OR 0.98, 95% Cl 0.89- 1.07, n= 93). It is notable that injection risk 
behaviours amongst participants in this study were low at baseline, with only 28% of participants 
who achieved 12 weeks follow up reporting ≥ daily injecting at enrolment. Moreover, the authors 
mention a lack of statistical power due to the relatively small sample size, providing a second 
explanation of lack of significant findings. A second study by Malaguti et al. (2019) investigated 
changes in weekly injecting frequency between enrolment, during treatment and at 6 months 
follow up. Results showed a significant decrease in injecting frequency between enrolment and 
future time points (χ2 (7) = 36.44, p< .001, n= 32), with the largest reduction in injecting reported 
between enrolment and week 8 of treatment, maintained through to 6 months follow up. A 
criticism of this study may be the high degree of incomplete data, with only 38% of participants 
providing data for all time points.  
Impact of treatment on needle and syringe borrowing 
The impact of treatment on needle and syringe borrowing was investigated by two studies. One 
such study by Alavi et al. (2015) found that treatment was not associated with a reduction in 
needle and syringe borrowing during follow up, when comparing PWID who did and did not 
receive treatment (aOR 0.99, 95% CI 0.89, 1.07, n= 124). A second study found that treatment 
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receipt did not significantly facilitate a reduction in use of non-sterile needles (OR 0.94; 95% CI 
0.79–1.12, n= 93) (Midgard et al., 2017). 
Impact of treatment on injecting equipment sharing 
Facilitation of a reduction in injecting equipment sharing by treatment was explored in three 
studies. One study reported a significant decrease in injecting equipment sharing, including 
mixing container, filter and water, during treatment and 24 weeks follow up (aOR 0.85, 95% CI 
0.74- 0.99, n=124), with a reduction in the number of participants reporting sharing from 54% at 
baseline to 17% at follow up (Alavi et al., 2015). In contrast Midgard et al. (2017) reported no 
association between treatment and injecting equipment sharing, including spoons, mixing 
containers, drug solution, water and filter, during treatment and 12 week follow up (OR 0.87, 
95% CI 0.70–1.07, n= 93). One study investigating the impact of DAA based treatment on 
behavioural outcomes reported a significant reduction in the number of participants reporting 
needle and syringe sharing during treatment and 2 year follow up (OR 0.87, 95% CI 0.80- 0.94, 
n= 190) (Artenie et al., 2019). However, it must be noted that although a reduction in needle and 
syringe sharing during and after treatment was noted, the baseline prevalence of this risk 
behaviour was low at only 16% of the 62% of participants who reported past month injecting.  
Discussion 
Summary of evidence 
In spite of the concerns around diagnosing and treating PWID for Hepatitis C, there is a dearth 
of research on the impact of engaging in treatment on behavioural change in relation to drug 
use in this population. The current review only identified five studies which directly measured 
behavioural change outcomes in PWID engaged in treatment. As a consequence of the limited 
number of studies identified, and variations in follow up times, behavioural outcomes, and 
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treatment interventions, drawing conclusions around whether treatment engagement is effective 
in reducing drug use and injecting risk behaviours is problematic.  
The most common outcome measure of behaviour change in relation to drug use in the selected 
studies was past month injecting drug use. Three of the four studies assessing this outcome 
found treatment significantly reduced the odds of participants reporting past month injecting at 
follow up (Artenie et al., 2017; Artenie et al., 2019; Midgard et al., 2017). However, due to 
variations in study design, comparing the findings of these separate studies is challenging. 
Accordingly, combining the data on these results to conduct a meta- analysis was deemed 
inappropriate. Additionally, it can be argued that dichotomously measuring past month injecting 
drug use is limiting in regards to providing insight into the impact of treatment on injecting 
behaviours. Combined with infrequent measurements of drug use, it could be suggested that 
the results of these studies simply reflect natural fluctuations in injecting frequency among 
PWID, and do not accurately reflect a reduction in drug use. However, taken together, these 
findings suggest that engaging in treatment may result in a possible reduction in injecting. This 
challenges critics who believe that treating PWID for Hepatitis C is not feasible due to concerns 
around treatment causing an increase in injecting risk behaviours (Schaefer, Sarker, & Diez- 
Quevedo, 2013). Moreover, these findings support the notion that treatment engagement may 
lower the risk of HCV transmission within the PWID population, providing support for 
accessibility to treatment. 
In regards to impact of treatment on other behavioural changes related to drug use, findings are 
more inconsistent. For instance, of the two studies which investigated the impact of treatment 
on injecting frequency, only one study observed a significant decline in injecting frequency 
between enrolment, treatment, and follow up (Malaguti et al., 2019). Nonetheless, comparing 
the findings of these studies is not suitable due to the contrasting measurements of injecting 
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frequency; namely weekly injecting, measured as a continuous variable (Malaguti et al., 2019), 
and ≥ daily injecting, measured as a binary variable (Midgard et al., 2017).  
Both studies investigating change in needle and syringe borrowing found no association 
between treatment engagement and reduction in these risk behaviours (Alavi et al., 2015; 
Midgard et al., 2017). Although no significant decline was observed in either study, the fact that 
such risk behaviours remain stable throughout treatment and follow up has meaningful 
implications for risk of reinfection and onward transmission. The minimisation of injecting risk 
behaviours after treatment is critical to optimise patients’ chances of achieving sustained viral 
responses and to reduce HCV prevalence at a population level (Hickman, De Angelis, 
Vickerman, Hutchinson, & Martin, 2015). Of the three studies investigating the impact of 
treatment on injecting equipment sharing, two studies reported significant decreases in such 
behaviour between enrolment, treatment and follow up. However, of these two studies, one 
study by Artenie et al. (2019) was conducted during the DAA era of treatment, making the 
findings of this study incomparable to the other studies investigating this behaviour change.  
Limitations of review 
The predominant limitation of the current review was the number of studies that met the 
inclusion criteria and the lack of comparability between studies. As a consequence, a meta- 
analysis of findings was not possible. Therefore, future reviews may seek to employ a more 
broadly inclusive eligibility criterion, including, for example, the inclusion of purely qualitative 
studies. Moreover, it is clear that future research should focus on the reasons why engaging in 
treatment facilitates a possible behavioural change in relation to drug use. A major limitation of 
the review was that four of the five selected studies were conducted during the interferon era of 
treatment. In particular, the characteristics of people undergoing interferon treatment may 
potentially be different to those undergoing DAA treatment. For example, those treated using 
interferon based therapy may have experienced more adverse treatment consequences, such 
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as associated psychiatric conditions, in comparison to those treated using the DAA based 
therapy. Moreover, the reasons why engaging in treatment facilitates a positive behaviour 
change in relation to drug may be disparate between the aforementioned treatment groups. 
Consequently, the results of the current review may not give insight into the impact of treatment 
on injecting risk behaviours in the new DAA based treatment era, with future research clearly 
needed to clarify this issue. Also, the review was hindered by the inclusion of studies with 
selection bias of participants. All five studies involved clinical trial participants, who were 
arguably more willing to engage in treatment than the source PWID population. This was 
characterised by relatively low lost to follow rates in some studies. Thus, the results of the 
included studies may not be representative of the wider population of PWID engaging in 
treatment.  
Conclusions 
Five studies investigating the impact of HCV treatment on behavioural change in relation to drug 
use amongst PWID were identified. The most common measure of behaviour change in relation 
to drug use was past month injecting drug use, with three out of four studies reporting treatment 
significantly reduced the odds of participants reporting past month injecting at follow up. Studies 
also reported significant reductions in injection equipment sharing between enrolment, treatment 
and follow up; no significant changes in needle and syringe borrowing; and varying results in 
regards to impact of treatment on injecting frequency. Comparison and synthesis of results was 
challenging due to heterogeneity of follow up times, treatment interventions, and measures of 
behavioural outcomes. For future research, it would be optimal for the research community to 
report injecting risk behaviour in a standardised manner to enable comparison and strengthen 
conclusions of published literature. Four out of the five selected studies were conducted during 
the interferon era of treatment, possibly limiting the generalisability of the current review’s 
results to the new DAA treatment era. However, results suggest the benefits of engaging in 
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HCV care stretch beyond liver morbidity outcomes, with treatment positively impacting on 
patients’ injecting drug use and injection equipment sharing behaviour. These findings have 
relevance to the “treatment as prevention” model of Hepatitis C care, risk of reinfection and 
onward HCV transmission (Schulkind et al., 2018; Fraser et al., 2018).  
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Figure 1. Search Strategy  
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Total records identified   
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Table 1  
Keyword search terms utilised in search strategy, grouped by search topic 
 
 
 
 
 
 
 
^MeSH/EMTREE terms 
 
 
Table 2 
Inclusion/Exclusion Criteria 
Inclusion Criteria 
 Participants: people who inject drugs (PWID). 
 Study intervention: Hepatitis C diagnosis and treatment (either interferon alpha or direct 
acting antivirals based). 
 Comparators: participants themselves i.e. behaviour measured before and after 
treatment; or PWID who did not receive treatment; or PWID who chose to not engage in 
treatment post HCV diagnosis. 
 Primary outcome: behavioural change in relation to drug use e.g. injecting behaviour, 
needle and syringe borrowing, sharing of ancillary equipment.  
 Studies published in English, utilising a quantitative or mixed- methods study design. 
Exclusion Criteria 
 Studies utilising a purely qualitative study design; individual case studies. 
 Studies that are entirely theoretical. 
 Participants who are non- injecting patients, or PWID who were treated for other blood 
borne viruses. 
 Studies investigating the impact of Hepatitis C treatment in prison populations. 
 Studies focusing on the impact of knowledge of HCV status, and not HCV treatment, on 
behavioural change in relation to drug use. 
 Studies focusing on reinfection rates after treatment. 
Hepatitis C treatment Behaviour change Drug use 
Hepatitis C 
treatment/therapy^ 
Behavi* change Drug abuse 
 
Interferon-alpha/ 
therapeutic use^ 
Behavi* benefit Drug misuse 
 Drug use change* Drug use 
 Inject behavi* Drug disorder 
 Risk behavi* Drug addict* 
 Inject* frequency Drug dependen* 
  Drug intravenous* 
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Table 3 
Summary of Study Characteristics 
Study 
 
Country 
Measure of 
behaviour 
change 
Design 
(comparison 
group(s)) 
 
Follow up period  
Setting Participant 
characteristics- 
age, gender, 
past month 
injecting drug 
use, on OST,  
HCV status 
Treatment Main Findings 
Alavi et al. 
(2015) 
 
Australia 
Past month  
Injecting drug 
use, used 
needle and 
syringe 
borrowing and 
ancillary 
injecting 
equipment 
sharing at 
baseline, 
throughout and 
after treatment 
Prospective 
cohort study 
(PWID that did 
not receive 
treatment)  
 
24 weeks  
Tertiary 
hospitals and 
GP/primary care 
clinics 
124 participants, 
Mean age= 32 
years (25- 39 
years), 69% 
male, past 
month injecting 
drug use= 45%, 
on OST= 18%, 
recent HCV 
infection. 
Pegylated 
interferon alpha 
and ribavirin 
treatment (up to 
24 weeks) 
 
Injecting drug 
use during 
follow up was 
not associated 
with treatment. 
Needle and 
syringe 
borrowing 
during follow up 
was not 
associated with 
treatment. 
Treatment 
associated with 
a reduction in 
ancillary 
injecting 
equipment 
sharing during 
follow up. 
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Artenie et al. 
(2017) 
 
Canada 
Past month 
injection drug 
use assessed 
dichotomously 
at 12 month 
treatment follow 
up 
 
Prospective 
cohort study 
(PWID who did 
not engage in 
treatment post-
diagnosis; did 
not engage due 
to spontaneous 
clearance; not 
eligible for 
treatment due to 
contra-
indications)  
 
1 year 
Community and 
hospital based 
clinics 
87 participants, 
Mean age= 35.6 
years, 78% 
male, past 
month injecting 
drug use= 
87.4%, on OST= 
37.9%, acute 
HCV infection. 
Pegylated 
interferon alpha 
and ribavirin 
treatment (up to 
24 weeks) 
 
Participants who 
received 
treatment were 
significantly less 
likely to report 
injection drug 
use at one-year 
follow-up 
compared to 
comparison 
groups. 
Artenie et al. 
(2019) 
 
Australia, 
Canada, New 
Zealand, 
Norway, 
Switzerland, 
France, UK and 
USA 
Past month 
injection drug 
use, needle/ 
syringe sharing, 
hazardous 
alcohol use 
during and 
following 
treatment  
Prospective 
cohort study 
(none) 
 
 
2 years 
Drug treatment 
clinics, hospital 
clinics, private 
practice, 
community 
clinics 
190 participants, 
Mean age= 47 
years, 74% 
male, past 
month injecting 
drug use= 62%, 
on OST= 61%, 
active HCV 
infection. 
Direct acting 
antivirals (12 
weeks) 
Overall 
decrease in 
opioid injecting 
during and 
following 
treatment. No 
changes found 
in hazardous 
alcohol 
consumption 
observed. 
Decrease in 
needle and 
syringe sharing 
during and 
following 
treatment. 
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Malaguti et al. 
(2019) 
 
United Kingdom 
Injecting 
frequency at 
baseline, 
throughout and 
after treatment  
Retrospective 
cohort study 
(none) 
 
 
6 months 
Injecting 
Equipment 
Provision (IEP) 
Service 
84 participants 
(18 to 70 years), 
69% male, past 
month injecting 
drug use= 
100%, on OST= 
71.4%, active 
HCV infection.  
Pegylated 
interferon alpha 
and ribavirin 
treatment (up to 
24 weeks) 
 
Significant 
reduction in 
injecting 
frequency 
between 
baseline and 
subsequent 
future time 
points. Largest 
reduction 
between week 1 
(baseline) and 
week 8. 
Midgard et al. 
(2017) 
 
Australia, 
Canada, 
Switzerland, 
Belgium, 
Germany, 
Norway and the 
UK 
Past month  
injection 
frequency, use 
of non-sterile 
needles, needle 
and syringe 
borrowing or 
lending, and 
injecting 
paraphernalia 
during and 
following 
treatment  
Prospective 
cohort study 
(none)  
 
 
24 weeks 
Hospital clinics, 
drug and alcohol 
clinics, office 
based practices 
and community 
clinics 
93 participants, 
Median age= 41 
years (35- 50 
years), 83% 
male, past 
month injecting 
drug use= 59%, 
on OST= 71%, 
chronic HCV 
infection. 
Pegylated 
interferon alpha 
and ribavirin 
treatment (up to 
24 weeks) 
 
Injecting drug 
use decreased 
during treatment 
and follow-up. 
No significant 
changes were 
found in >daily 
injecting, use of 
non-sterile 
needles, sharing 
of injecting 
paraphernalia, 
or non-injecting 
drug use. 
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Table 4 
Quality appraisal ratings for each included study 
 Alavi et al. 
(2015) 
Artenie et al. 
(2017) 
Malaguti et al. 
(2019) 
Midgard et al. 
(2017) 
Artenie et al. 
(2019) 
1.1 Description of source population 3 3 3 3 1 
1.2 Representativeness of eligible population 3 3 3 3 2 
1.3 Representativeness of selected participants 2 3 2 2 2 
2.1 Allocation to intervention or comparison NA NA NA NA NA 
2.2 Description of intervention and comparison 3 3 2 3 2 
2.3 Concealment of allocation NA NA NA NA NA 
2.4 Blinding to exposure/comparison NA NA NA NA NA 
2.5 Adequacy of exposure to intervention/comparison NA NA NA NA NA 
2.6 Contamination NA NA NA NA NA 
2.7 Similarity of other interventions to groups 3 3 NA NA NA 
2.8 Lost to follow up  1 2 2 2 1 
2.9 Setting reflects usual UK practice 2 2 3 3 2 
2.10 Intervention reflects usual UK practice 2 2 3 3 2 
3.1 Reliability of outcome measures 1  1 1 1 1 
3.2 Completion of outcome measures 3 3 3 3 3 
25
3.3 Assessment of important outcomes NA NA NA NA NA 
3.4 Relevance of outcomes 3 3 3 3 3 
3.5 Similarity of follow up times across groups NA NA NA NA NA 
3.6 Meaningfulness of follow up times 3 3 3 3 3 
4.1 Similarity of groups at baseline 3 3 NA NA NA 
4.2 Intention to treat (ITT) analysis NA NA NA NA NA 
4.3 Study’s power to detect an intervention effect 2 2 2 2 2 
4.4 Estimates of effect size 3 3 3 3 3 
4.5 Appropriateness of analytical methods  3 3 3 3 2 
4.6 Precision of intervention effects 3 3 3 3 3 
5.1 Internal validity  2 3 2 2 2 
5.2 External validity 3 3 3 3 3 
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